Inolimomab is under investigation as an agent to treat steroid-resistant graft vs host disease. It has thus far offered similar efficacy to other monoclonal antibody options, though it may carry...
- Mechanism
- Curator reviewed · 2 references
Inolimomab is a murine monoclonal antibody targeting CD-25, also known as the alpha subunit of the interleukin-2 receptor. The binding of this antibody to CD-25 blocks the signaling of interleukin-2, preventing clonal expansion of T-cells. The resulting immunosuppressive effect appears to provide a similar benefit in patients with steroid-resistant graft vs host disease to anti-thymocyte globulin.
- Code names
- BT-563
Resolves to
What you can answer from here — as of June 15, 2026
Which drugs share a target with Inolimomab, and which of those have an active Phase 3 trial?
Create a free account or log in to explore the full data card.
Create Account